NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D, will present at Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 10:30 a.m EDT at the InterContinental Boston Hotel in Boston, MA. To access live audio broadcast of this presentation, or the subsequent 90 day archive, log onto http://wsw.com/webcast/canaccord6/sgyp/ About Synergy Pharmaceuticals, Inc. Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com .
CONTACT: Danielle Spangler The Trout Group email@example.com (646) 378-2924